StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.24−0.16 (-6.67%)

Close on Nov 16, 2026Market cap $5.06MP/E –Yield –

Biodexa Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Biodexa Pharmaceuticals's cash was £3.23M at Jun 30, 2026. For fiscal 2025 it was £8.53M, up 411.3% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is £30.33M in fiscal 2014.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025£8.53M+411.3%
FY2024Dec 31, 2024£1.67M-72.0%
FY2023Dec 31, 2023£5.97M+110.5%
FY2022Dec 31, 2022£2.84M-71.8%
FY2021Dec 31, 2021£10.06M+33.3%
FY2020Dec 31, 2020£7.55M-30.9%
FY2019Dec 31, 2019£10.93M+366.4%
FY2018Dec 31, 2018£2.34M-82.3%
FY2017Dec 31, 2017£13.20M-25.0%
FY2016Dec 31, 2016£17.61M+8.9%
FY2015Dec 31, 2015£16.18M-46.7%
FY2014Dec 31, 2014£30.33M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026£3.23M-36.1%
Q4 FY2025Dec 31, 2025£8.53M+42.9%
Q2 FY2025Jun 30, 2025£4.04M-22.8%
Q4 FY2024Dec 31, 2024£1.67M-41.1%
Q2 FY2024Jun 30, 2024£5.06M-21.3%
Q4 FY2023Dec 31, 2023£5.97M-40.6%
Q2 FY2023Jun 30, 2023£5.23M-30.7%
Q4 FY2022Dec 31, 2022£2.84M-74.0%
Q2 FY2022Jun 30, 2022£6.42M+174.1%
Q4 FY2021Dec 31, 2021£10.06M-23.8%
Q4 FY2020Dec 31, 2020£7.55M-57.1%
Q4 FY2019Dec 31, 2019£10.93M-32.4%
Q4 FY2018Dec 31, 2018£2.34M-92.3%
Q4 FY2017Dec 31, 2017£13.20M–
Q4 FY2016Dec 31, 2016£17.61M–
Q4 FY2015Dec 31, 2015£16.18M–
Q4 FY2014Dec 31, 2014£30.33M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?